Carr, Tara F.
Moore, Wendy C.
Kraft, Monica
Brusselle, Guy
Castro, Mario
Chupp, Geoffrey L.
Wechsler, Michael E.
Hunter, Gillian
Lindsley, Andrew W. http://orcid.org/0000-0003-2670-704X
Llanos, Jean-Pierre http://orcid.org/0000-0002-7785-6881
Burke, Luke K.
Chandarana, Shradha
Ambrose, Christopher S. http://orcid.org/0000-0003-4175-7336
Clinical trials referenced in this document:
Documents that mention this clinical trial
M23 Efficacy of tezepelumab in patients with severe, uncontrolled asthma by prior omalizumab use: a post hoc analysis of the phase 3 NAVIGATOR study
https://doi.org/10.1136/thorax-2023-btsabstracts.412
M21 On-treatment clinical remission with tezepelumab in patients with severe, uncontrolled asthma in the phase 3 DESTINATION study
https://doi.org/10.1136/thorax-2023-btsabstracts.410
Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study
https://doi.org/10.1007/s12325-024-02889-8
S48 Efficacy of tezepelumab according to age at asthma onset in NAVIGATOR
https://doi.org/10.1136/thorax-2022-btsabstracts.54
S47 DESTINATION: tezepelumab long-term safety and efficacy versus placebo in patients with severe, uncontrolled asthma
https://doi.org/10.1136/thorax-2022-btsabstracts.53
S67 Biomarkers and clinical outcomes after cessation of tezepelumab after 2 years of treatment (DESTINATION)
https://doi.org/10.1136/thorax-2023-btsabstracts.73
S119 Effect of tezepelumab in patients with severe, uncontrolled asthma by age of onset, allergic status, and eosinophilic phenotype
https://doi.org/10.1136/thorax-2023-btsabstracts.125
Effect of Tezepelumab on Lung Function in Patients With Severe, Uncontrolled Asthma in the Phase 3 NAVIGATOR Study
https://doi.org/10.1007/s12325-023-02659-y
S49 Effect of tezepelumab on a composite of severe asthma exacerbations and acute worsening events, CompEx, in the phase 3 NAVIGATOR study
https://doi.org/10.1136/thorax-2022-btsabstracts.55
S65 Tezepelumab reduced OCS use in OCS-dependent patients with severe asthma: phase 3b WAYFINDER study interim results
https://doi.org/10.1136/thorax-2023-btsabstracts.71
M26 The proportion of patients achieving low biomarker levels with tezepelumab treatment in the phase 3 NAVIGATOR study
https://doi.org/10.1136/thorax-2023-btsabstracts.415
Funding for this research was provided by:
AstraZeneca
Amgen, Inc.
Article History
Received: 8 March 2024
Accepted: 29 April 2024
First Online: 27 May 2024
Declarations
:
: Tara F. Carr has served in an advisory role or as a consultant for AstraZeneca, Genentech, GSK, Novartis and Regeneron Pharmaceuticals. Wendy C. Moore has received consultancy fees for participation in advisory boards from AstraZeneca, GSK, Regeneron Pharmaceuticals and Sanofi; her institution has received research support from AstraZeneca, Boehringer-Ingelheim, Genentech, Gossamer Bio, GSK, Regeneron Pharmaceuticals, Sanofi, Suzhou Pharmaceuticals, Teva Pharmaceuticals and the US National Heart, Lung, and Blood Institute/US National Institutes of Health. Monica Kraft has received research support from the American Lung Association, AstraZeneca, Janssen, Sanofi, Synairgen and the US National Institutes of Health, with funds paid to the University of Arizona and Mount Sinai Health System; has received personal fees from AstraZeneca, Chiesi, Genentech, Kinaset and Sanofi; and is a cofounder and Chief Medical Officer for RaeSedo, Inc. Guy Brusselle has received fees for participation in advisory boards and/or speaker fees from Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, MSD, Novartis and Sanofi. Mario Castro has received grants/research support from ALA, AstraZeneca, Gala Therapeutics, Genentech, GSK, Novartis, Patient-Centered Outcomes Research Institute, Pulmatrix, Sanofi-Aventis, Shionogi, Theravance and the US National Institutes of Health; has received consulting fees/honoraria from Allakos, Amgen, Arrowhead, AstraZeneca, Genentech, Merck, Novartis, OM Pharma, Regeneron Pharmaceuticals, Sanofi and Teva Pharmaceuticals; and has received royalties from Aer Therapeutics and Elsevier. Geoffrey L. Chupp has received speaker and consultancy fees from Amgen, AstraZeneca, Boehringer Ingelheim, Genentech, GSK, Novartis, Regeneron Pharmaceuticals, Sanofi-Genzyme and Teva Pharmaceuticals. Michael E. Wechsler is an employee of National Jewish Health and has received consultancy fees from AstraZeneca, Equillium, Genentech, GSK, Novartis, Regeneron Pharmaceuticals, resTORbio, Sanofi and Teva Pharmaceuticals. Gillian Hunter, Luke K. Burke, Shradha Chandarana and Christopher S. Ambrose are employees of AstraZeneca and may own stock or stock options in AstraZeneca. Andrew W. Lindsley and Jean-Pierre Llanos are employees of Amgen and own stock in Amgen.
: The study was conducted in accordance with the ethical principles of the Declaration of Helsinki, International Council for Harmonisation Good Clinical Practice guidelines and applicable regulatory requirements. Approvals from the Copernicus Central Institutional Review Board (Cary, NC, USA) and local independent ethics committees were obtained, and all patients or their guardians provided written informed consent in accordance with local requirements.